Loring Wolcott & Coolidge Fiduciary Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $106 | Hold |
3
| – | – | ﹤0.01% | 563 |
|
|
2026
Q1 | $79 | Hold |
3
| – | – | ﹤0.01% | 559 |
|
|
2025
Q4 | $101 | Hold |
3
| – | – | ﹤0.01% | 533 |
|
|
2025
Q3 | $79 | Hold |
3
| – | – | ﹤0.01% | 527 |
|
|
2025
Q2 | $51 | Hold |
3
| – | – | ﹤0.01% | 518 |
|
|
2025
Q1 | $49 | Hold |
3
| – | – | ﹤0.01% | 559 |
|
|
2024
Q4 | $59 | Hold |
3
| – | – | ﹤0.01% | 559 |
|
|
2024
Q3 | $39 | Buy |
+3
| New | +$35 | ﹤0.01% | 570 |
|
|
2024
Q2 | – | Sell |
-3
| Closed | -$31 | – | 576 |
|
|
2024
Q1 | $31 | Hold |
3
| – | – | ﹤0.01% | 562 |
|
|
2023
Q4 | $32 | Hold |
3
| – | – | ﹤0.01% | 554 |
|
|
2023
Q3 | $22 | Hold |
3
| – | – | ﹤0.01% | 606 |
|
|
2023
Q2 | $35 | Hold |
3
| – | – | ﹤0.01% | 629 |
|
|
2023
Q1 | $36 | Hold |
3
| – | – | ﹤0.01% | 592 |
|
|
2022
Q4 | $41 | Hold |
3
| – | – | ﹤0.01% | 573 |
|
|
2022
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 630 |
|
|
2022
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 673 |
|
|
2022
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 701 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 764 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 900 |
|
|
2021
Q2 | $0 | Buy |
+3
| New | +$113 | ﹤0.01% | 951 |
|
|
2021
Q1 | – | Sell |
-3
| Closed | – | – | 610 |
|
|
2020
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 794 |
|
|
2020
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 607 |
|
|
2020
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 638 |
|
|
2020
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 698 |
|
|
2019
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 705 |
|
|
2019
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 724 |
|
|
2019
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 757 |
|
|
2019
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 748 |
|
|
2018
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 723 |
|
|
2018
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 672 |
|
|
2018
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 720 |
|
|
2018
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 786 |
|
|
2017
Q4 | $1K | Hold |
3
| – | – | ﹤0.01% | 707 |
|
|
2017
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 882 |
|
|
2017
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 650 |
|
|
2017
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 626 |
|
|
2016
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 612 |
|
|
2016
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 637 |
|
|
2016
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 646 |
|
|
2016
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 642 |
|
|
2015
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 668 |
|
|
2015
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 612 |
|
|
2015
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 625 |
|
|
2015
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 635 |
|
|
2014
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 637 |
|
|
2014
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 612 |
|
|
2014
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 635 |
|
|
2014
Q1 | $1K | Hold |
3
| – | – | ﹤0.01% | 613 |
|
|
2013
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 610 |
|
|
2013
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 563 |
|
|
2013
Q2 | $0 | Buy |
+3
| New | +$136 | ﹤0.01% | 594 |
|
Other funds holding RIGL
HWAM
BC
Loring Wolcott & Coolidge Fiduciary Advisors's RIGL Position: Q2 2026 in Review
Loring Wolcott & Coolidge Fiduciary Advisors held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 3 shares worth $106. The position accounts for ﹤0.01% of the portfolio, ranked #563.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in RIGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $1K in Q4 2017. 46 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors held 3 shares of Rigel Pharmaceuticals worth $106 as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
- Rigel Pharmaceuticals made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #563 holding.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Loring Wolcott & Coolidge Fiduciary Advisors's Rigel Pharmaceuticals position peaked at $1K in Q4 2017.
- 46 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.